Medimscience

Medimscience is an emerging biotechnology company in China that is the first to focus on the development of new target drugs for macrophages in the tumor immune microenvironment. Tumor immunotherapy drugs are currently the most important means of treating cancer, but existing treatments mainly based on T cells have obvious limitations, while drugs targeting macrophages are expected to address the shortcomings of current tumor immunotherapy drugs and treatment methods. The Hangzhou Medimscience Biomedical Technology Co., Ltd. research and development team is also committed to providing comprehensive technical services for antibody drug development as well as phased technical services for various stages of the antibody drug development process.